

Reconsideration of the application is respectfully requested.

### I. AMENDMENT

#### In the Specification:

Please amend the specification as follows:

On the first page, before the first sentence of the specification, please insert --/This

Q<sup>1</sup> application claims priority to pending U.S. Application No. 08/726,211, filed 10/04/1996.--

therefor.

#### In the Claims:

Please amend the following claims:

1. (Amended) A composition comprising [a first] a P-ethoxy polynucleotide that hybridizes to a [second,] Bcl-2-encoding polynucleotide under intracellular conditions and a neutral lipid associated with said [first] P-ethoxy polynucleotide [, and wherein said composition contains no cationic lipid] to form a neutrally-charged polynucleotide/lipid association.
- Q<sup>2</sup> 2. (Amended) The composition of claim 1, wherein said [first] P-ethoxy polynucleotide is an oligonucleotide having a length of between about 8 and about 50 bases.
3. (Amended) The composition of claim 1, wherein the [first] P-ethoxy polynucleotide is complementary to the translation initiation site of Bcl-2 mRNA.
5. (Amended) The composition of claim 1, comprising a liposome formed from the neutral lipid.
6. (Amended) The composition of claim 5, wherein the [first] P-ethoxy polynucleotide is encapsulated in the liposome.
- Q<sup>3</sup> 7. (Amended) The composition of claim 1, wherein the neutral lipid is a phosphatidylcholine, a phosphatidylglycerol, or a phosphatidylethanolamine.
8. (Amended) The composition of claim 7, wherein the neutral lipid is dioleoylphosphatidylcholine.